GT Medical Technologies, Inc. news
Drs. Ondrej Choutka, MD, a neurosurgeon, and Lindsay Sales, MD, a radiation oncologist at Saint Alphonsus Regional Medical Center in Boise, have become the first doctors in the Pacific Northwest to utilize a new treatment for brain tumors. They implanted the FDA-cleared GammaTile therapy in a 44-year-old patient with a malignant brain tumor.
The current standard of care for patients
GT Medical Technologies, Inc. today announced it was named a winner of the Innovator of the Year in the small company category at the 2021 Governor`s Celebration of Innovation, presented live on stage by the Arizona Technology Council and the Arizona Commerce Authority on October 13. GT Medical Technologies received this accolade in recognition of GammaTile® Therapy, its Surgically Targeted Radiation Therapy (STaRT),
GT Medical Technologies, Inc. today announced it is presenting clinical data in two oral presentations on the company`s breakthrough GammaTile® Therapy for patients with brain tumors at the 2021 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting. The presenting authors, Dr.&n
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT Medical Technologies’ GammaTile Surgically Targeted Radiation Therapy (STaRT) for treatment of recurrent glioblastoma (GBM). Novocure’s TTFields are electric fields that disrupt cancer cell division. GammaTile is an FDA-cleared therapy for the treatment of all types of brain tumor
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering Ga
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering Ga
GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced the first patient has been enrolled into its registry trial of GammaTile®, a FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for newly diagnosed malignant and recurrent brain tumo